AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15463836 — intervention group
Group type: COMPARATOR
Intervention: Inhaled colistin
Number of subjects: 0
Study 15463836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin nebuliser solution (TNS) and Inhaled colistin
Number of subjects: 0
Study 10071997 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion of 0.1 microg x kg(‐1) x min(‐1) and saline bolus (5 mL)
Number of subjects: 45
Study 10071997 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion and remifentanil bolus (25 microg in 5 mL)
Number of subjects: 45
Study 10071997 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion of 0.05 microg x kg(‐1) x min(‐1) and remifentanil bolus (12.5 microg in 5 mL)
Number of subjects: 45
Study 10071997 — intervention group
Group type: COMPARATOR
Intervention: Variable-rate continuous infusion of remifentanil
Number of subjects: 45
Study 7585853 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin
Number of subjects: 260
Study 7585853 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 260
Study 7585853 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin and TMP-SMX
Number of subjects: 260
Study 2342129 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium sulfate (4 g/day for 14 days)
Number of subjects: 57
Study 2342129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 2342129 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium sulfate
Number of subjects: 57
Study 6108607 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride 100 mg (89.4 mg of ranitidine base) twice daily
Number of subjects: 49
Study 6108607 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets twice daily
Number of subjects: 49
Study 6108607 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride (open treatment)
Number of subjects: 49
Study 31150662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting phase (light and heavy objects)
Number of subjects: 0
Study 31150662 — intervention group
Group type: COMPARATOR
Intervention: Holding phase (light and heavy objects)
Number of subjects: 0
Study 27992099 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised home-based telerehabilitation (TG)
Number of subjects: 36
Study 27992099 — intervention group
Group type: COMPARATOR
Intervention: Usual care without exercise training (CG)
Number of subjects: 36
Study 25913479 — intervention group
Group type: EXPERIMENTAL
Intervention: AML-BFM 04 treatment protocol
Number of subjects: 97
Study 25913479 — intervention group
Group type: COMPARATOR
Intervention: AML-BFM 98 treatment protocol
Number of subjects: 97
Study 25913479 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation in first remission
Number of subjects: 97
Study 25913479 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain of chromosome 21
Number of subjects: 97
Study 25913479 — intervention group
Group type: EXPERIMENTAL
Intervention: Translocation t(1;22)(p13;q13)
Number of subjects: 97
Study 25913479 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment response (bone marrow morphology on day 15 and 28)
Number of subjects: 97
Study 23539081 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on a motorized, polyethylene high-resistance flywheel for 9 sessions
Number of subjects: 23
Study 23539081 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on ice for 9 sessions
Number of subjects: 23
Study 23539081 — intervention group
Group type: COMPARATOR
Intervention: Control subjects who did not practice crossovers
Number of subjects: 23
Study 21413548 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 0
Study 21413548 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 0
Study 21413548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19791705 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Delivery Incentive Programme (SDIP) cash transfer
Number of subjects: 0
Study 19791705 — intervention group
Group type: COMPARATOR
Intervention: No women's groups
Number of subjects: 0
Study 17538878 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 80
Study 17538878 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (3TC)
Number of subjects: 80
Study 15031350 — intervention group
Group type: EXPERIMENTAL
Intervention: pH‐neutral low‐GDP solution (Balance)
Number of subjects: 17
Study 15031350 — intervention group
Group type: COMPARATOR
Intervention: Conventional solution (S‐PDF)
Number of subjects: 17
Study 11840198 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Assisted Learning (CAL) package
Number of subjects: 48
Study 11840198 — intervention group
Group type: COMPARATOR
Intervention: Conventional teaching (20 min mini-lecture)
Number of subjects: 48
Study 9725758 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (15 mg, orally)
Number of subjects: 0
Study 9725758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9725758 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual task condition (visual discrimination task)
Number of subjects: 0
Study 9725758 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource depletion hypothesis
Number of subjects: 0
Study 8000101 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (L-deprenyl) at a dose of 7.5 mg/day (Group D, n = 60)
Number of subjects: 112
Study 8000101 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P, n = 52)
Number of subjects: 112
Study 8000101 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (L-deprenyl) (Group D)
Number of subjects: 112
Study 8000101 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 112
Study 2647130 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (100 mg three times daily, increasing to 200 mg three times daily where required)
Number of subjects: 152
Study 2647130 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 152
Study 2647130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 2647130 — intervention group
Group type: COMPARATOR
Intervention: Labetalol and Placebo
Number of subjects: 152
Study 1092285 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 64
Study 1092285 — intervention group
Group type: COMPARATOR
Intervention: Imipramine hydrochloride
Number of subjects: 64
Study 31736189 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for identifying MGUS cases using electronic health data.
Number of subjects: 833
Study 31168802 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous crenezumab (300mg) every 2 weeks
Number of subjects: 104
Study 31168802 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous crenezumab (15mg/kg) every 4 weeks
Number of subjects: 104
Study 31168802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 28683829 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 39
Study 28683829 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study 26489055 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative repair with hook plate fixation
Number of subjects: 83
Study 26489055 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 83
Study 23369412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad4-H5-Vtn (10^11 viral particles)
Number of subjects: 166
Study 23369412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 23369412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad4-H5-Vtn (all doses combined)
Number of subjects: 166
Study 21452293 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept (25 mg, 75 mg, or 150 mg)
Number of subjects: 256
Study 21452293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 17562086 — intervention group
Group type: EXPERIMENTAL
Intervention: Support-group intervention (for 11 CT-RT and 10 RT patients)
Number of subjects: 41
Study 17562086 — intervention group
Group type: COMPARATOR
Intervention: Control group (remaining patients not receiving support intervention)
Number of subjects: 41
Study 16606972 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative docetaxel (T) added to doxorubicin and cyclophosphamide (AC)
Number of subjects: 2411
Study 16606972 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative docetaxel (T)
Number of subjects: 2411
Study 16606972 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative docetaxel (T)
Number of subjects: 2411
Study 16606972 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of T to AC
Number of subjects: 2411
Study 16606972 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic nodal status after chemotherapy
Number of subjects: 2411
Study 12488303 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m², 3-weekly cycles, up to 3 cycles)
Number of subjects: 274
Study 12488303 — intervention group
Group type: COMPARATOR
Intervention: Control (no chemotherapy)
Number of subjects: 274
Study 12488303 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m²)
Number of subjects: 274
Study 12488303 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 274
Study 11826920 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivot drawer test
Number of subjects: 100
Study 11826920 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion rotation drawer test
Number of subjects: 100
Study 11826920 — intervention group
Group type: EXPERIMENTAL
Intervention: Slocum test
Number of subjects: 100
Study 11826920 — intervention group
Group type: COMPARATOR
Intervention: Lachman test
Number of subjects: 100
Study 11826920 — intervention group
Group type: COMPARATOR
Intervention: KT‐1000 knee ligament arthrometer
Number of subjects: 100
Study 9087387 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma) therapy
Number of subjects: 50
Study 1438493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital (150 mg)
Number of subjects: 29
Study 1438493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 3515952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 70
Study 3515952 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 70
Study 30430635 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face group (FG) attending 12 Go group lessons once a week
Number of subjects: 72
Study 30430635 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-face-to-face group (NFG) using a tablet for the same Go lessons
Number of subjects: 72
Study 30430635 — intervention group
Group type: COMPARATOR
Intervention: Health education control group (CG)
Number of subjects: 72
Study 29250907 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome sequencing for preconception carrier screening
Number of subjects: 51
Study 29250907 — intervention group
Group type: COMPARATOR
Intervention: Usual care (single disease carrier testing)
Number of subjects: 51
Study 26811534 — intervention group
Group type: EXPERIMENTAL
Intervention: CELF4 rs1786814 GG genotype with anthracycline exposure > 300 mg/m2
Number of subjects: 0
Study 26811534 — intervention group
Group type: EXPERIMENTAL
Intervention: CELF4 rs1786814 GG genotype
Number of subjects: 0
Study 25268802 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg or higher
Number of subjects: 116
Study 25268802 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 116
Study 25268802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 22791245 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of 50 mg atenolol
Number of subjects: 24
Study 22791245 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of 50 mg atenolol
Number of subjects: 24
Study 19460188 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 943
Study 17363758 — intervention group
Group type: EXPERIMENTAL
Intervention: Entity theorists
Number of subjects: 0
Study 17363758 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit theories of groups manipulated via instruction set
Number of subjects: 0
Study 17363758 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of group entitativity
Number of subjects: 0
Study 17363758 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit theory
Number of subjects: 0
Study 12204875 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS)
Number of subjects: 73
Study 12204875 — intervention group
Group type: COMPARATOR
Intervention: Control device (inactive oral appliance)
Number of subjects: 73
Study 10037433 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg finasteride per day for 6 months
Number of subjects: 0
Study 8791113 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex antioxidant treatment for 3 years
Number of subjects: 0
Study 8791113 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in fresh fruits and vegetables
Number of subjects: 0
Study 8791113 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants with or without H. pylori eradication
Number of subjects: 0
Study 1812476 — intervention group
Group type: EXPERIMENTAL
Intervention: Euphylong (once daily at 2000 hours)
Number of subjects: 0
Study 1812476 — intervention group
Group type: COMPARATOR
Intervention: Conventional theophylline treatment (twice daily at 800 and 2000 hours)
Number of subjects: 0
Study 7086761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (three-dose perioperative course)
Number of subjects: 82
Study 7086761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 31893705 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix-based formulation of the iterative randomized stimulation and averaging (IRSA) method
Number of subjects: 0
Study 31893705 — intervention group
Group type: COMPARATOR
Intervention: Conventional IRSA method
Number of subjects: 0
Study 31893705 — intervention group
Group type: COMPARATOR
Intervention: Least-squares (LS) deconvolution
Number of subjects: 0
Study 29140440 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal behavioral lifestyle intervention (diet and physical activity)
Number of subjects: 344
Study 29140440 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal glycemia (specifically fasting glucose at 28 weeks gestation)
Number of subjects: 344
Study 29140440 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component of cord blood phosphatidylcholines and LPCs
Number of subjects: 344
Study 29140440 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood insulin growth factor (IGF)-1 and adiponectin concentrations
Number of subjects: 344
Study 26398674 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole granule
Number of subjects: 34
Study 26398674 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole suspension
Number of subjects: 34
Study 24156664 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home interdisciplinary chronic illness care management intervention
Number of subjects: 80
Study 24156664 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 22699176 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing program
Number of subjects: 58
Study 22699176 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 19557207 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 534
Study 17536074 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs)
Number of subjects: 162
Study 15888501 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultant rheumatologist workshops
Number of subjects: 138
Study 15888501 — intervention group
Group type: COMPARATOR
Intervention: Nurse clinical educator workshops
Number of subjects: 138
Study 12572374 — intervention group
Group type: EXPERIMENTAL
Intervention: Huatan Zhuyu Jiedu Decoction (HZJD)
Number of subjects: 100
Study 12572374 — intervention group
Group type: COMPARATOR
Intervention: Duhuo Jisheng Decoction
Number of subjects: 100
Study 9448347 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded and sealed composite restorations
Number of subjects: 0
Study 9448347 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed conservative amalgam restorations
Number of subjects: 0
Study 9448347 — intervention group
Group type: COMPARATOR
Intervention: Conventional unsealed amalgam restorations
Number of subjects: 0
Study 7874943 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 24
Study 7874943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2191867 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 133
Study 2191867 — intervention group
Group type: COMPARATOR
Intervention: TMP‐SMZ
Number of subjects: 133
Study 373989 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid (1500 mg for 2 weeks)
Number of subjects: 24
Study 373989 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (150 mg for 2 weeks)
Number of subjects: 24
Study 373989 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (150 mg for 2 weeks)
Number of subjects: 24
Study 373989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31984696 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic combination (Lactobacillus and Bifidobacterium with fructo‐ and galacto‐oligosaccharides)
Number of subjects: 25
Study 31984696 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 25
Study 31593091 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild physical activity intensity
Number of subjects: 252
Study 31593091 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity intensity
Number of subjects: 252
Study 31593091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense physical activity intensity
Number of subjects: 252
Study 31593091 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity at work
Number of subjects: 252
Study 31593091 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational activities
Number of subjects: 252
Study 27982726 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 12
Study 27982726 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 12
Study 25870084 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 44
Study 25870084 — intervention group
Group type: COMPARATOR
Intervention: Standard advice for diet and exercise (Control)
Number of subjects: 44
Study 24473536 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (150-μg testosterone patch)
Number of subjects: 128
Study 24473536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 24473536 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 128
Study 21885724 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) for 1 month
Number of subjects: 35
Study 21885724 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle counseling (Control)
Number of subjects: 35
Study 19672840 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized linear mixed models (GLMM)
Number of subjects: 0
Study 19672840 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical models (Bayes-HM)
Number of subjects: 0
Study 19672840 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized estimating equations (GEE)
Number of subjects: 0
Study 19672840 — intervention group
Group type: COMPARATOR
Intervention: Two-sample t-test of cluster-level rates
Number of subjects: 0
Study 19672840 — intervention group
Group type: COMPARATOR
Intervention: Generalized estimating equations (GEE) with empirical covariance estimators
Number of subjects: 0
Study 19672840 — intervention group
Group type: COMPARATOR
Intervention: Generalized estimating equations (GEE) with model-based covariance estimators
Number of subjects: 0
Study 17711873 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-Finding Approach
Number of subjects: 0
Study 17711873 — intervention group
Group type: COMPARATOR
Intervention: McKenzie Approach
Number of subjects: 0
Study 15194332 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (intravenous bolus injection on day 0 and day 4)
Number of subjects: 28
Study 15194332 — intervention group
Group type: COMPARATOR
Intervention: Matched historical control group (n = 28)
Number of subjects: 28
Study 11156873 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen plus progestin
Number of subjects: 2763
Study 11156873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2763
Study 9158829 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma bicarbonate concentration
Number of subjects: 141
Study 9158829 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentrations of free fatty acids (FFA), acetone, and the sum of 3-hydroxybutyrate (3OHB) and lactate
Number of subjects: 141
Study 9158829 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma FFA/albumin molar ratio
Number of subjects: 141
Study 9158829 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial anion gap
Number of subjects: 141
Study 9158829 — intervention group
Group type: COMPARATOR
Intervention: Plasma glucose and lactate concentrations
Number of subjects: 141
Study 8480985 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg)
Number of subjects: 17
Study 8480985 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg)
Number of subjects: 17
Study 2434787 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (5 mg intravenous injections every 4 min, mean total 38 mg)
Number of subjects: 20
Study 2434787 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 20
Study 2434787 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (10 mg sublingually)
Number of subjects: 20
Study 31541426 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day acceptance and commitment therapy (ACT) workshop
Number of subjects: 32
Study 29581669 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) for 4 sessions with 3 day-intervals
Number of subjects: 60